3 key reasons behind Bitcoin's record high today
Broader factors are helping too. Easing tensions between the US and China and a fresh Moody's downgrade of US debt have pushed some investors to see Bitcoin as a safer place for their money.Simply put, while crypto markets are always unpredictable, this record high has once again put Bitcoin in the spotlight. Traders and investors will now be watching closely to see if this rally can hold steady or if the price will slip back again, as it often has in the past.For now, Bitcoin holders are enjoying the ride, and hoping this is just the beginning of another big bull run.- EndsMust Watch
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
26 minutes ago
- The Hindu
OpenAI, Oracle deepen AI data center push with 4.5 gigawatt Stargate expansion
OpenAI and Oracle will develop another 4.5 gigawatts of data center capacity, expanding a tie-up that has promised hundreds of billions of dollars in infrastructure investment to keep the U.S. ahead in the global artificial intelligence race. The ChatGPT maker did not disclose the locations or funding details for the new facilities in Tuesday's announcement. The move builds on the Stargate initiative, an up to $500 billion and 10 gigawatt project that also includes Japanese technology investor SoftBank Group and is setting up its first AI data center in Abilene, Texas. OpenAI, as well as its backer Microsoft, are among the technology companies pouring billions of dollars on data centers to power generative AI services such as ChatGPT and Copilot that require huge amounts of computing power. The growing use of AI in sensitive sectors such as defense, as well as China's push to catch up, has made the nascent technology a top priority for U.S. President Donald Trump, who unveiled Stargate at the White House in January. The new data centers will bring Stargate's total capacity under development to more than 5 gigawatts, which will run on over 2 million chips, OpenAI said in a blog post, adding that the tie-up now expects to exceed its initial commitment. Oracle did not immediately respond to a Reuters request for comment, while the White House declined to comment. Analysts have raised doubts about the venture's ability to secure the funding, including $100 billion for immediate deployment. In January, xAI owner Elon Musk, dismissed the group, saying "they don't actually have the money." OpenAI and SoftBank will each commit $19 billion to fund Stargate, reports said in January. The Wall Street Journal reported on Monday the two companies have been at odds with each other and Stargate is now setting a more modest goal of building a small data center at end-2025, likely in Ohio.
&w=3840&q=100)
Business Standard
26 minutes ago
- Business Standard
Tesla's California EV sales fall for 7th straight quarter amid weak demand
A total of 41,138 Teslas were registered in the state last quarter, a 21 per cent drop year over year for the company's seventh straight quarterly decline Bloomberg The number of new Tesla Inc. vehicles registered in California fell once again as the company continued to lose ground in the largest US market for electric vehicles. A total of 41,138 Teslas were registered in the state last quarter, a 21 per cent drop year over year for the company's seventh straight quarterly decline, the California New Car Dealers Association said Tuesday. Tesla's tumble exceeded the 13 per cent dip in total zero-emission vehicle registrations in the state during the same period. The results highlight the magnitude of Tesla's ongoing sales slump. The carmaker's global deliveries tumbled 13 per cent in the second quarter, and analysts expect the EV maker to log a second straight annual decline this year, according to the average of estimates compiled by Bloomberg. The company is contending with an aging vehicle lineup, growing competition in the EV market and a consumer backlash to Chief Executive Officer Elon Musk's work with the Trump administration, even after the billionaire's public falling out with the president. California registrations of Tesla's top-selling Model Y declined 37 per cent in the the first half of the year. That came as it introduced a freshened version of the small SUV. The company had blamed weak first-quarter sales in part on factory shutdowns related to the update of the key model. The report, which cites data from Experian, comes a day before Tesla is expected to report second-quarter earnings, with investors looking for an update on key plans for Tesla's automotive business, including progress on more-affordable vehicles that could reignite consumer interest. Still, Tesla's top-selling Model Y and Model 3 vehicles continue to be two of the most popular models in the largest auto market in the US. The Model Y SUV was the top-selling vehicle of any kind, with more than 44,000 registered during the first six months, while the Model 3 was the No. 1-selling passenger car.
Mint
26 minutes ago
- Mint
Donald Trump threatens to use import restrictions on foreign drugmakers to reduce prices — Does it affect India?
US President Donald Trump on Tuesday threatened to use import restrictions to force foreign suppliers to reduce drug prices. Speaking at the White House at an event with Republican lawmakers, Trump further warned pharma companies to face a 'lot of problems' if they do not agree to reduce the drug prices in the US. Trump pledged to reduce what consumers must pay for prescription drugs. 'Drug companies will have lot of problems if they don't agree to bring prices down,' he said, making hinting at plans to use trade policy as leverage. 'We are going to get drug prices down… We will use import restrictions to force foreign suppliers to cut drug prices.' The US President's statement comes more than a month after he signed a broad executive order in June directing drugmakers to lower the prices of their prescription drugs to align with what other countries pay. The order said the Trump administration will give drugmakers price targets within a month and, if they fail to make "significant progress", may pursue regulatory actions or measures like importing medicines -- though analysts and legal experts say such steps would be difficult to implement. India plays a key role in supplying pharmaceutical products to the US, including generic drugs and active pharmaceutical ingredients (APIs). According to a report by The Times of India, New Delhi supplies around 35 per cent of all generic drugs prescribed in the US. Therefore, Trump's order to force foreign drugmakers to cut drug prices using import restrictions could significantly affect them, coupled with the fact that India and US have not signed a trade deal as yet. However, in June, Crisil Ratings had said Donald Trump's executive order on reducing prescription drug prices will have a limited impact on Indian pharma companies. Citing the reason behind its observation, the credit rating firm in its report said that despite India exporting over half of its pharmaceutical output, the bulk comprises low-priced generic drugs, which already operate on razor-thin margins, leaving little room for further price cuts to materially affect revenues. "API exports (15 per cent of India's pharma exports) are expected to be broadly unaffected, as it is not a major cost for high-margin originator drugs, abating concerns of pricing pressure," the report said. Generic pharma drugs account for 90 per cent of the prescription sales volume but only 13 per cent of the value spending in the US. Generic drug prices in the US are very low and have lower prices in comparison to economically peer countries, it said.
